









## 5. CONCLUSION

Angiotensin II receptor type I (AT<sub>1</sub>) blocker telmisartan protected LPS intoxicated murine RAW 264.7 cell line by attenuating the NFκB activation thereby controlling the expression of pro inflammatory mediator TNFα, which might be an independent mechanism. Telmisartan a functional modulator of PPARγ hence, the link between PPARγ and NFκB mediated inflammatory mechanism need to be explored to further ascertain the telmisartan protective activity.

## REFERENCE

- [1] Timmermans, P. B, Wong, P. C, Chiu, A.T, Herblin, W. F, Benfield, P, Carini, D. J, *Pharmacol. Rev.* 1993, 45, 205–251.
- [2] Neldam, S, *Future. Cardiol.* 2010, 6, 129–135.
- [3] Benson, S. C, Pershadsingh, H. A, Ho, C. I, Chittiboyina, A, Desai, P, Pravenec, M, *Hypertension.* 2004, 43, 993–1002.
- [4] Rotman, N, Wahli, W, *Physiology (Bethesda).* 2010, 25, 176–185.
- [5] Duan, S. Z, Usher, M. G, Mortensen, R, M, *Curr. Opin. Nephrol. Hypertens.* 2009, 18, 128–133.
- [6] Bregonzio, C, Armando, I, Ando, H, Jezova, M, Baiardi, G, Saavedra, J. M, *Am. J. Physiol Gastrointest. Liver. Physiol.* 2003, 285, 414–423.
- [7] Sanchez, L. E, Benicky, J, Pavel, J, Saavedra, J, M, *Brain. Behav. Immun.* 2009, 23, 945–957.
- [8] Larrayoz, I. M, Pang, T, Benicky, J, Pavel, J, Sanchez, L. E, *J. Hypertens.* 2009, 27, 2365–2376.
- [9] Klotz, L, Sastre, M, Kreutz, A, Gavrilyuk, V, Klockgether, T, Feinstein, D. L, Heneka, M,T, *J. Neurochem.* 2003, 86, 907–916.
- [10] Escribano, L, Simon, A. M, Perez, M. A, Salazar, C. P, Del, R. J, Frechilla, D, Rosiglitazone *Biochem. Biophys. Res. Commun.* 2009, 379, 406–410.
- [11] Watson, G. S, Cholerton, B. A, Reger, M. A, Baker, L. D, Plymate, S. R, Asthana, S, Fishel M. A, Kulstad, J. J, Green, P. S, Cook, D. G, Kahn, S. E, Keeling, M. L, Craft, S, *Am. J. Geriatr. Psychiatry,* 2005, 13, 950–958.
- [12] Stuart, A, Rushworth, Xi, L. C, Nigel, M, Richard, M, Ogborne, Maria, A, O'Connell, *J. Immunol.* 2005, 175, 4408-4415.
- [13] Tao, P, Julius, B, Juan, W, Martina, O, Enrique, S. L, Saavedra, J. M, *J. Hypertens.* 2012, 30, 87–96.
- [14] An, J, Nakajima, T, Kuba, K, Kimura, A. *Hypertens Res.* 2010, 33, 831–835.
- [15] Tao, P, Juan, W, Julius, B, Enrique S. L, Saavedra, J. M, *J. Neuroinflammation,* 2012, 9, 102
- [16] Yong, C. L, Wen, C. Y, Pamela, S. O, *Cytokine.* 2008, 42, 145–151.
- [17] Jinlei, L. V, Ruhan, J, Dingping, Y, Jili, Z, Guohua, D, *Biochem. Biophys. Res. Commun.* 2009, 55, 81–86.
- [18] Tsuneyasu, K, Shizuo, A, *J. Allergy Clin. Immunol.* 2006, 117, 979–987.
- [19] Tham, D. M, Martin, M. B, Wang, Y. X, Wilson, D. W, Vergona, R, Sullivan, M. E, Dole, W, Rutledge, J. C, *Physiol. Genomics.* 2002, 11, 21–30.
- [20] Gonzalez, S. F, Baltuch, G, 1999. *Annu. Rev. Neurosci.* 1999, 22, 219–240.
- [21] Sriram, K, Matheson, J. M, Benkovic, S. A, Miller, D. B, Luster, M. I, O'Callaghan, J. P, *FASEB. J.* 2006, 20, 670–682.
- [22] Sriram, K, Matheson, J. M, Benkovic, S. A, Miller, D. B, Luster, M. I, O'Callaghan, J. P, *FASEB. J.* 2002, 16, 1474–1476.